Tetra Pharm Technologies ApS
CVR number: 40738223
Søndre Jernbanevej 11, 3400 Hillerød
contact@tetrapharm.eu
Income statement (kDKK)
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 |
| Net sales | ||||
| Gross profit | - 926.10 | 3 208.29 | 584.76 | |
| Costs of management | -12 871.24 | -15 785.76 | ||
| Costs of distribution | -8 067.08 | -23 615.71 | ||
| Employee benefit expenses | - 146.33 | -3 534.92 | ||
| Total depreciation | -72.52 | -87.60 | ||
| EBIT | -1 144.96 | - 414.24 | -20 938.32 | -38 816.71 |
| Other financial income | 0.03 | 422.78 | ||
| Other financial expenses | -6.11 | -87.64 | -58.52 | -6.94 |
| Pre-tax profit | -1 151.07 | - 501.87 | -20 996.81 | -38 400.87 |
| Income taxes | 253.22 | 807.47 | 1 432.64 | 5 454.00 |
| Net earnings | - 897.85 | 305.59 | -19 564.18 | -32 946.87 |
Assets (kDKK)
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Development expenditure | 3 168.39 | |||
| Intangible assets total | 3 168.39 | |||
| Buildings | 221.01 | 580.01 | 3 583.91 | 14 174.62 |
| Machinery and equipment | 116.71 | 138.96 | ||
| Tangible assets total | 337.72 | 718.97 | 3 583.91 | 14 174.62 |
| Other receivables | 138.00 | 922.31 | 916.33 | 1 133.14 |
| Investments total | 138.00 | 922.31 | 916.33 | 1 133.14 |
| Non-current other receivables | 3 859.28 | |||
| Long term receivables total | 3 859.28 | |||
| Semifinished products | 3 048.97 | |||
| Inventories total | 3 048.97 | |||
| Prepayments and accrued income | 63.83 | |||
| Current other receivables | 119.37 | 311.22 | 1 213.59 | 2 739.96 |
| Current deferred tax assets | 253.22 | 1 060.69 | 2 150.21 | 7 604.21 |
| Short term receivables total | 436.42 | 1 371.90 | 3 363.79 | 10 344.17 |
| Cash and bank deposits | 5 198.40 | 60 916.54 | 8 927.62 | |
| Cash and cash equivalents | 5 198.40 | 60 916.54 | 8 927.62 | |
| Balance sheet total (assets) | 912.14 | 18 288.23 | 68 780.58 | 34 579.55 |
Equity and liabilities (kDKK)
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Share capital | 40.00 | 48.08 | 62.39 | 62.39 |
| Share premium account | 1.65 | 15 027.86 | 90 009.59 | 90 009.59 |
| Other reserves | 2 471.36 | |||
| Retained earnings | -4 066.24 | -5 473.13 | -25 037.30 | |
| Profit of the financial year | - 897.85 | 305.59 | -19 564.18 | -32 946.87 |
| Shareholders equity total | - 856.20 | 13 786.65 | 65 034.68 | 32 087.81 |
| Provisions | 697.03 | |||
| Non-current trade creditors | 28.26 | 194.89 | ||
| Non-current owed to group member | 2 637.63 | |||
| Non-current other liabilities | 1 356.80 | |||
| Non-current deferred tax liabilities | 972.04 | |||
| Non-current liabilities total | 1 385.06 | 3 804.55 | ||
| Current loans from credit institutions | 383.27 | |||
| Current trade creditors | 2 478.03 | 1 332.20 | ||
| Current owed to participating | 1 321.12 | |||
| Other non-interest bearing current liabilities | -1 321.12 | 1 267.87 | 1 159.53 | |
| Current liabilities total | 383.27 | 3 745.90 | 2 491.73 | |
| Balance sheet total (liabilities) | 912.14 | 18 288.23 | 68 780.58 | 34 579.55 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.